We have reached the first position, in December 2019, in the international inclusion of patients in the trial with sublingual apomorphine and motor blocks in Parkinson. We are also leading the national inclusion of patients in the Clarity AD trial (monoclonal anti-amyloid antibody in early Alzheimer) Finally, in the Graduate trial (monoclonal subcutaneous in Alzheimer)…
The UDIC has been selected to initiate a line of several clinical trials with this D1 dopamine agonist, with a similar mechanism of action to Apomorphine. It will be evaluated in initial Parkinson’s and also in advanced Parkinson’s disease, as add on levodopa therapy. An open label extension is planned.
The UDIC will start a new clinical trial that evaluates the subcutaneous administration of levodopa, using a continuous perfusion pump, to treat motor fluctuations in advanced Parkinson’s isease. It will compare with standard Levodopa in a double-blind study. Up to now this has not been possible due to high volume required. This “ultra concentrated” levodopa…
New formulation of combined action Levodopa We have started the evaluation of a new preparation of Levodopa, in capsules, with several wrapping layers, which allow a delay in the digestive release, an immediate effect and a later delayed effect. It would have the advantages of a Levodopa retard type Rytary, but with a combined effect…
We have started a clinical trial with a new antidiskinetic therapy (combination of two drugs already authorized in other indications) to evaluate its safety and efficacy in patients with severe dyskinesia in advanced Parkinson’s disease. The aim is to study a safer therapy and with a lower risk than the invasive therapies currently used .
Our clinical trials unit will start a new phase I trial in patients with early Parkinson’s disease. Patients will be included in different cohorts, single dose and ascending doses, in patients with or without mutations in the LRRK2 gene, by means of an intrathecal administration of an antisense oligonucleotide. Only 62 patients will participate in…